ECSP099385A - Formas cristalinas de hemifumarato de aliskiren - Google Patents

Formas cristalinas de hemifumarato de aliskiren

Info

Publication number
ECSP099385A
ECSP099385A EC2009009385A ECSP099385A ECSP099385A EC SP099385 A ECSP099385 A EC SP099385A EC 2009009385 A EC2009009385 A EC 2009009385A EC SP099385 A ECSP099385 A EC SP099385A EC SP099385 A ECSP099385 A EC SP099385A
Authority
EC
Ecuador
Prior art keywords
crystal forms
aliskiren hemifumarate
manufacture
pharmaceutical
hemifumarate
Prior art date
Application number
EC2009009385A
Other languages
English (en)
Inventor
Stephanie Monnier
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37907983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099385A publication Critical patent/ECSP099385A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a formas de cristal de hemifumarato de aliskiren y diferentes modalidades relacionadas con la misma, por ejemplo, preparaciones farmacéuticas, procesos para la manufactura de las formas de cristal, usos farmacéuticos y similares. Las formas de cristal tienen propiedades particularmente ventajosas, por ejemplo, útiles en la manufactura de una preparación farmacéutica para disminuir la presión sanguínea, y similares.
EC2009009385A 2006-11-07 2009-06-04 Formas cristalinas de hemifumarato de aliskiren ECSP099385A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06123642 2006-11-07

Publications (1)

Publication Number Publication Date
ECSP099385A true ECSP099385A (es) 2009-07-31

Family

ID=37907983

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009385A ECSP099385A (es) 2006-11-07 2009-06-04 Formas cristalinas de hemifumarato de aliskiren

Country Status (25)

Country Link
US (1) US8119841B2 (es)
EP (1) EP2079463A1 (es)
JP (1) JP2010508370A (es)
KR (1) KR20090083918A (es)
CN (1) CN101594857B (es)
AR (1) AR063560A1 (es)
AU (1) AU2007323465B2 (es)
BR (1) BRPI0718546A2 (es)
CA (1) CA2668828A1 (es)
CL (1) CL2007003194A1 (es)
CO (1) CO6180428A2 (es)
EC (1) ECSP099385A (es)
GT (1) GT200900116A (es)
IL (1) IL198470A0 (es)
MA (1) MA30921B1 (es)
MX (1) MX2009004885A (es)
MY (1) MY148758A (es)
NO (1) NO20092102L (es)
NZ (1) NZ577320A (es)
PE (2) PE20121179A1 (es)
RU (1) RU2466982C2 (es)
TN (1) TN2009000174A1 (es)
TW (1) TW200827326A (es)
WO (1) WO2008061622A1 (es)
ZA (1) ZA200902941B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029083A1 (en) * 2007-11-13 2012-02-02 Teva Pharmaceutical Industries, Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
CA2712087A1 (en) 2008-01-23 2009-07-30 Novartis Ag Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
EP2393489B1 (en) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
US8148576B2 (en) * 2009-02-05 2012-04-03 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
CN102617392B (zh) * 2011-01-28 2015-04-01 博瑞生物医药技术(苏州)有限公司 一种阿利克仑半富马酸盐晶型ⅰ的制备方法
ITMI20111291A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato etil acetato solvato
ITMI20111290A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato, forma cristallina e solido amorfo
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
BR0112362B1 (pt) * 2000-07-05 2013-12-31 Processo para a preparação de octanoil amidas substituídas e compostos intermediários
RU2316318C2 (ru) * 2002-05-17 2008-02-10 Новартис Аг Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2007323465A1 (en) 2008-05-29
MX2009004885A (es) 2009-05-19
RU2009121651A (ru) 2010-12-20
PE20121179A1 (es) 2012-09-13
CO6180428A2 (es) 2010-07-19
CN101594857A (zh) 2009-12-02
NO20092102L (no) 2009-07-30
JP2010508370A (ja) 2010-03-18
CA2668828A1 (en) 2008-05-29
CL2007003194A1 (es) 2008-06-13
US8119841B2 (en) 2012-02-21
AU2007323465B2 (en) 2011-08-04
PE20081157A1 (es) 2008-09-26
MA30921B1 (fr) 2009-11-02
MY148758A (en) 2013-05-31
WO2008061622A1 (en) 2008-05-29
TN2009000174A1 (en) 2010-10-18
GT200900116A (es) 2011-06-07
AR063560A1 (es) 2009-02-04
TW200827326A (en) 2008-07-01
EP2079463A1 (en) 2009-07-22
CN101594857B (zh) 2012-10-31
US20100048716A1 (en) 2010-02-25
NZ577320A (en) 2012-01-12
ZA200902941B (en) 2010-03-31
RU2466982C2 (ru) 2012-11-20
KR20090083918A (ko) 2009-08-04
IL198470A0 (en) 2010-02-17
BRPI0718546A2 (pt) 2013-11-19

Similar Documents

Publication Publication Date Title
ECSP099385A (es) Formas cristalinas de hemifumarato de aliskiren
CR10406A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CU23586A1 (es) Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
CL2007003389A1 (es) Formas cristalinas de sales de acido zoledronico; composicion farmaceutica; y uso en el tratamiento del cancer.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
HN2012001321A (es) Analogo peptidico de oxintomodulina
ECSP10010580A (es) Inmunoglobulinas duales de dominio variable y sus aplicaciones
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
DK2178796T3 (da) Kontinuerlig fremgangsmåde til behandling af væsker og fremstilling af visse bestanddele
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
BRPI1010550A2 (pt) formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substãncias ativas fracamente solúveis e, água.
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
GT200500031A (es) Procesos para la preparacion de haluros de arilalquilsulfonilo y haluros de heteroarilalquilsulfonilo
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
MA32635B1 (fr) Produit medicamenteux et traitement associe
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
WO2010149383A3 (de) Ceramid-dimere und ihre verwendung als arzneimittel oder kosmetische zubereitung
BR112012028906A2 (pt) polimorfos de benzoato de alogliptina